1. Gene Signature–Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn's Disease. Issue 6 (13th April 2018) Authors: Gamo, Kanae; Okuzono, Yuumi; Yabuki, Masato; Ochi, Takashi; Sugimura, Kyoko; Sato, Yosuke; Sagara, Masaki; Hayashi, Hiroki; Ishimura, Yoshimasa; Nishimoto, Yutaka; Murakawa, Yusuke; Shiokawa, Zenyu; Gotoh, Masayuki; Miyazaki, Takahiro; Ebisuno, Yukihiko Journal: Inflammatory bowel diseases Issue: Volume 24:Issue 6(2018) Page Start: 1251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Gene Signature–Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn's Disease. Issue 6 (18th May 2018) Authors: Gamo, Kanae; Okuzono, Yuumi; Yabuki, Masato; Ochi, Takashi; Sugimura, Kyoko; Sato, Yosuke; Sagara, Masaki; Hayashi, Hiroki; Ishimura, Yoshimasa; Nishimoto, Yutaka; Murakawa, Yusuke; Shiokawa, Zenyu; Gotoh, Masayuki; Miyazaki, Takahiro; Ebisuno, Yukihiko Journal: Inflammatory bowel diseases Issue: Volume 24:Issue 6(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗